Synlogic Inc · OTC:SYBX

Synlogic — Q3 2021 Earnings Presentation

25 slides from Synlogic's earnings presentation, Nov 10, 2021

  1. Slide 1: Q3 Financial Results & Business Update

    Bringing the Transformative Power of Synthetic Biology to Medicine Q3 Financial Results & Business Update 10 November 2021 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Opening Remarks

    © 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Opening Remarks Dr. Aoife Brennan MB CHB President & CEO

  4. Slide 4: Q3 program highlights across solid tumors, IBD and metabolic programs

    Solid Tumors SYNB1891 combination study with PD-1 has completed enrollment. No further studies planned at this time Inflammatory Bowel Disease Advancing research collaboration with Roche on novel IBD target; achieved first milestone Metabolic programs Immunology Multiple high value indications acces

  5. Slide 5: Robust pipeline moving forward

    Phenylketonuria (PKU) SYNB1618 Inflammatory Bowel Disease Enteric Hyperoxaluria SYNB8802 SYNB1618 Homocystinuria Undisclosed Metabolic Program PoC 2022 Combo study late ‘21 Robust pipeline moving forward Metabolic Metabolite consumption in the GI tract Immunology SYNB1934 Undisclosed IBD Program Exp

  6. Slide 6: Progress against our strategy

    Progress against our strategy PKU Demonstrated plasma Phe lowering in patients with classical PKU PKU Demonstrated higher potency of next generation strain in humans HOX Progressed Phase 1B study IBD Achieved first Roche research collaboration milestone Other Metabolic Advanced third oral metabolic

  7. Slide 7: Synthetic Biotic Medicines: Differentiated Potential in PKU

    Synthetic Biotic Medicines: Differentiated Potential in PKU Molly Harper Chief Business Officer

  8. Slide 8: PKU: Significant Disease Burden, Need for New Treatment Options

    PKU: Significant Disease Burden, Need for New Treatment Options Inherited defects in PAH enzyme impairs ability to metabolize Phe Neurocognitive risk remains: 8X risk for intellectual disabilities1 70% had significant neuropsych comorbidity (50% had multiple)2 1 Bilder et al. 2017; 2 Levy et al. 202

  9. Slide 9: Current options leave behind the majority that live with PKU

    Current options leave behind the majority that live with PKU Self-injection, daily 6-12 month titration Boxed warning: anaphylaxis “at any time during treatment” Restricted REMS Only approved for adults4 30% response rate1 10% mean fasting Phe reduction for all-comers2 Adult daily pill burden can ex

  10. Slide 10: Synthetic Biotic Medicines are designed for PKU

    Synthetic Biotic™ Medicines are designed for PKU Taken orally, 3 x day with meals Monotherapy or adjunctive Local delivery, without systemic AEs Dietary Phe Reduce plasma Phe Converted by Synthetic Biotic to harmless metabolites (TCA)

  11. Slide 11: Interim Analysis of SYNB1618 SynPheny-1 Phase Study in PKU

    Interim Analysis of SYNB1618 SynPheny-1 Phase 2 Study in PKU

  12. Slide 12: Synthetic Biotic Medicines: a novel approach in PKU

    Synthetic Biotic Medicines: a novel approach in Phenylketonuria (PKU) Potential to treat all PKU patients with a safe oral approach Synthetic Biotic Medicines Meaningful data: two trials with interim results Current and emerging treatment options leave many patients behind PKU SYNB1618 strain achiev

  13. Slide 13: SynPheny-1 study in PKU: Design

    6-day diet run in Individualized diet plan to match baseline Phe intake Stable study diet: diet run-in through 2 weeks post treatment Diet Control Endpoints Fasting Plasma Phe levels (day -1, 7, 14, 29) Labelled D5-Phe 24hr AUC, change from baseline after meal challenge (day -1, 15) Day 29 Fasting P

  14. Slide 14: SYNB1618 metabolized Phe into TCA and prevented Phe absorption

    SYNB1618 metabolized Phe into TCA and prevented Phe absorption after meal challenge Percent change from baseline +/- 95% confidence interval. TCA = trans-cinnamic acid. AUC = Area under curve. 4 of 8 patients experienced >40% D5-Phe lowering after meal challenge TCA Production Phe absorption into pl

  15. Slide 15: SYNB1618 reduced fasting plasma Phe levels

    SYNB1618 reduced fasting plasma Phe levels Fasting Plasma Phe Levels (N=8) Percent change from baseline +/- 95% confidence interval. * = Statistically significant Cessation of treatment 4 of 8 patients experienced >30% reduction in fasting Plasma Phe at Day 7 or Day 14

  16. Slide 16: SYNB1934 demonstrated two-fold improvement over SYNB1618

    Mean +/- 90% confidence interval. TCA = trans-cinnamic acid HA = hippuric acid SYNB1934 demonstrated two-fold improvement over SYNB1618 in biomarkers of Phe metabolism SYNB1934 and SYNB1618 D5-TCA and D5-HA N = 12 SYNB1934 Developed from SYNB1618 using directed evolution Potential for increased Phe

  17. Slide 17: SYNB1934 expectation of improved clinical profile

    Healthy volunteers PKU Patients SYNB1618 1e12 dose SYNB1934 1e12 dose 7% D5-Phe reduction post-meal 27% D5-Phe reduction post-meal 20% Fasting plasma Phe Expectation of improved clinical profile SYNB1934 to be evaluated in new arm of SynPheny-1 study

  18. Slide 18: Enteric Hyperoxaluria (HOX)

    Enteric Hyperoxaluria (HOX) Enteric Hyperoxaluria results in significant, irreversible, and progressive kidney damage SYNB8802 proof of mechanism established: potential for best-in-class urinary oxalate lowering Proof of concept data expected 2022

  19. Slide 19: An innovative oral approach in an area of high unmet medical need

    Oral therapy An innovative approach in an area of high unmet medical need Our approach Consume Oxalate in the GI Tract Reduce Oxalate in the urine Differentiation from other approaches Ph 1B Proof of Concept in Enteric Hyperoxaluria patients (Roux-en-Y population) initiated Consumes oxalate in each

  20. Slide 20: SYNB8802 Demonstrates Dose-related Oxalate consumption

    SYNB8802 Demonstrates Dose-related Oxalate consumption * LS mean change over Placebo, +/- 90% CI, all days baseline and treated % Change Urinary Ox over Placebo % Change in Fecal Oxalate Consistent evidence of oxalate consumption across endpoints in dietary hyperoxaluria in healthy volunteers ASN Ki

  21. Slide 21: SYNB8802 3e11 dose advancing to Ph1B in patients

    SYNB8802 3e11 live cells dose advancing to Ph1B in patients LS mean change over Placebo, +/- 90% std error of mean, all days; and 24hr UOx after 5 days of dosing, +/- 90% std error of mean. 600mg daily oxalate. Change in UOx UOx Levels Clinically meaningful lowering of urinary oxalate demonstrated a

  22. Slide 22: Third Quarter 2021 Summary Results

    Balance Sheet (unaudited) 30 September 2021 31 December 2020 Cash, Cash Equivalents, and Marketable Securities $150.1 M $100.4 M Statement of Operations (unaudited) 30 September 2021 30 September 2020 R&D Expenses $13.4 M $10.5 M G&A Expenses $3.6 M $3.0 M Net Loss $16.0 M $13.2 M Net loss per share

  23. Slide 23: Concluding Remarks

    © 2020 SYNLOGIC. QU©AR2TE1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 1414 Concluding Remarks Dr. Aoife Brennan MD CHB President & CEO

  24. Slide 24: Synlogic continues to deliver meaningful data

    Synlogic continues to deliver meaningful data Robust portfolio with significant milestones over the next 18 months PKU Enteric Hyperoxaluria SYNB8802 Ph1B proof of concept read-out H1 2022 2021 SYNB1934 Ph2 SynPheny proof of concept read-out SYNB1618 Delivered SYNB1934 Head to Head data in HV SYNB19

  25. Slide 25: Available For Questions

    Available For Questions Dave Hava, PhD Chief Scientific Officer Caroline Kurtz, PhD Chief Development Officer Daniel Rosan Head of Finance & Investor Relations Aoife Brennan, MB ChB President & CEO Antoine Awad Chief Operating Officer Gregg Beloff, JD MBA Interim CFO Molly Harper Chief Business Offi

Synlogic — Q3 2021 Earnings Presentation on 6ix